Life
Briefing: GOP Senator Investigates FDA Over Rare Disease Drug Rejections
Strategic angle: Sen. Ron Johnson raises concerns about the FDA's handling of treatments for rare diseases after discussions with Commissioner Marty Makary.
editorial-staff
1 min read
Updated about 1 month ago
Summary
- Sen. Ron Johnson is questioning the FDA's drug approval process.
- Focus on treatments for rare diseases that have been rejected.
- Discussion with FDA Commissioner Marty Makary highlights concerns.
Key Facts
| Fact | Value |
|---|---|
| Senator | Ron Johnson |
| Agency | FDA |
| Date of Investigation | March 10, 2026 |